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ABSTRACT 
Background: Aspirin use is known to reduce the recurrence of stroke. However, the clinical 
response to aspirin has been mixed. The rate of stroke recurrence whilst on aspirin treatment 
is still unacceptably high. A plausible explanation for this may be resistance to the effects of 
aspirin. The causes of aspirin resistance are manifold and multi-factorial. We conducted a 
study to investigate the prevalence rate of biochemical aspirin resistance in a cohort of aspi-
rin-naïve stroke patients. We also sought to determine the inherent factors that may predis-
pose towards the development of aspirin resistance.  
Method: This was a cross-sectional, observational study conducted on patients admitted to 
our centre with an acute stroke who were aspirin-naïve. The diagnosis of an acute stroke was 
confirmed by clinical history and brain imaging. Fifty consecutive patients were prospectively 
enrolled. Socio-demographic data were collected and baseline blood investigations were per-
formed. Patients were tested for biochemical aspirin resistance using Multiplate platelet 
analyser (Dynabyte, Munich, Germany) after 5 doses of aspirin, corresponding to a total dose 
of 900 mg.  
Results: The median age of patients was 65.5 years and 54 % of patients were female. There 
were 11 smokers; of these 10 were male. Twenty-six (52 %) patients were Chinese, 21 (41 %) 
were Malay and 3 (6.0 %) were Indian. Aspirin resistance was present in 14 % of our patients. 
There was an inverse relationship between the presence of aspirin resistance and plasma HDL 
levels (r = -0.394; p = 0.005). There was no relationship observed between aspirin resistance 
and total cholesterol, triglycerides, LDL, HbA1c, ALT, ALP, urea and creatinine levels. 
There were no significant differences in demographic profiles or smoking status between the 
aspirin resistant and non-aspirin resistant groups. We did not find any link between ethnicity 
and aspirin resistance. 
Conclusions: Our results indicate that a lower HDL level is associated with biochemical aspi-
rin resistance. This may increase platelet aggregation and consequently increase the risk of a 
recurrent stroke. The clinical implications for aspirin resistance are far reaching. Any evi-
dence that correctable factors may negatively influence the action of aspirin warrants further 
investigation. The prevalence rate of biochemical aspirin resistance in our study is compara-
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ble to the findings in other studies performed in an Asian population. Further research is re-
quired to determine how our findings translate into clinical aspirin resistance and stroke recur-
rence. 
 
Keywords: ischaemic stroke, aspirin resistance, antiplatelet therapy, Asia, developing coun-
tries, risk factors, aspirin 
 
 
INTRODUCTION 
It is estimated that there were 5.7 mil-
lion stroke deaths worldwide in 2005. By 
2015, this number is predicted to rise to 6.5 
million and the majority of cases will be in 
developing economies (Strong et al., 2007). 
Correspondingly, stroke related disability 
was judged to be the sixth most common 
cause of reduced disability-adjusted life-
years (DALYs), and is expected to be the 
fourth most common cause in 2030 (Mur-
ray and Lopez, 1997; Lopez et al., 2006). 
From an economic standpoint, worldwide 
stroke consumes 2-4 % of total health care 
costs (Donnan et al., 2008). All these facts 
and figures underline the importance of 
proper secondary prevention of stroke.  
Secondary prevention of stroke involves 
adequate risk factor control (Davis and 
Donnan, 2012). Aspirin remains the stand-
ard first-line anti-platelet therapy in the 
secondary prevention of stroke in develop-
ing economies due to its low-cost. Aspirin 
use results in a 13 % to 25 % reduction in 
stroke recurrence (Algra and van Gijn, 
1996). However, as many as three-quarters 
of patients may still suffer a recurrence of 
stroke whilst on aspirin treatment (An-
tithrombotic Trialists’ Collaboration, 2002). 
This could be due to biochemical aspirin re-
sistance that leads to a failure to inhibit 
platelet aggregation.  
There are several reasons why aspirin 
resistance is thought to occur. NSAIDs 
competitively bind to the COX-1 substrate 
binding site and adversely influence the ef-
fectiveness of platelet inhibition by aspirin 
(Capone et al., 2005). Concomitant use of 
proton-pump inhibitors (PPI) may reduce 
the enteral absorption of aspirin (Würtz et 
al., 2010). Inherent patient factors may also 
play a role in the development of aspirin re-
sistance. Single nucleotide polymorphism 
(SNP) in platelet genes can affect the plate-
let inhibition of aspirin (Hankey and 
Eikelboom, 2006). Studies have shown that 
there is an increase in the prevalence of as-
pirin resistance in patients with diabetes (Di 
Chiara et al., 2007). Hypertriglyceridaemia 
has been demonstrated to adversely affect 
the platelet response to aspirin (Karepov et 
al., 2008). Reduced platelet responsiveness 
to aspirin is associated with a worse stroke 
severity at onset (Schwammental et al., 
2008). 
The aim of this study was to investigate 
the prevalence of biochemical aspirin re-
sistance in acute ischaemic stroke patients 
who were aspirin naïve. We also investigat-
ed patient factors that might contribute to-
wards the development of aspirin re-
sistance. We used the Multiplate platelet 
analyser to measure biochemical aspirin re-
sistance in our sample of patients. 
 
MATERIALS AND METHODS 
This was a cross-sectional observational 
study conducted at UKM Medical Centre 
from May 2009 to November 2009. Con-
secutive patients who were admitted with 
an acute stroke during the recruitment peri-
od were screened. Aspirin naïve patients 
who were confirmed to have a stroke based 
on clinical examination and imaging find-
ings were invited to participate. Patients 
who provided informed consent had blood 
drawn for baseline investigations, which in-
cluded Full Blood Count (FBC), Renal Pro-
file (RP), Liver Function Test (LFT), 
HbA1c and Fasting Serum Lipid (FSL), as 
part of routine blood investigation at this 
centre. Patients were excluded if they were 
EXCLI Journal 2013;12:907-915 – ISSN 1611-2156 
Received: July 04, 2013, accepted: October 21, 2013, published: October 29, 2013 
 
 
909 
allergic to aspirin, had recent NSAID’s, an-
tiplatelet or anticoagulant therapy, and had 
any form of blood disorders, recent or past 
history of haemorrhagic strokes, liver fail-
ure and any history of gastrointestinal 
bleeding.  
On day 1, patients were given 300 mg 
of aspirin as a loading dose, followed by 
150 mg daily thereafter for 5 days. On day 
5, 4.5 ml of venous blood was collected. 
The samples were stored in vials containing 
heparin-lithium as the anti-coagulating 
agent.  
The study complies with the Declara-
tion of Helsinki and was approved by the 
hospital ethics committee. 
 
Measurement of aspirin resistance using 
Multiplate platelet analyser 
The analysis of platelet function was 
carried out using the Multiplate platelet 
analyser (Dynabyte, Munich, Germany), a 
whole blood impedance aggregometer. The 
method for using Multiplate has been de-
scribed in greater detail elsewhere (Calatzis 
et al., 2004, 2005; Toth et al., 2006). In 
brief, the device has 5 test cells, and each 
test cell has 2 independent sensor units. The 
system works on the principle of increased 
electrical impedance between the two sen-
sor wires caused by activation of platelet 
adhesion and aggregation. Arachidonic acid 
(AA) (ASPItest, 0.5 mM) was used to initi-
ate platelet aggregation. The increased im-
pedance caused by aggregation of platelets 
onto the sensor wires was recorded for 
6 minutes. The data from the aggregation of 
platelets onto the sensor wires were con-
verted to arbitrary units labeled as “AU”. 
The converted data is then plotted as a 
graph of aggregation curve versus time. The 
area under the aggregation curve was la-
beled as AUC*min. An AUC*min value of 
> 440 was defined as ‘biochemical aspirin 
resistance’ (von Pape et al., 2007). 
All data were analysed using SPSS 16.0 
for Mac statistical software package. 
Quantitative and qualitative demographic 
characteristics were summarized and data 
were tabulated and tested for normality us-
ing Shapiro-Wilk test because the sample 
was below 100.  
Categorical variables were analyzed us-
ing 2 test whereas continuous variables 
were analysed using Mann-Whitney U test. 
Associations between parameters were ex-
amined using Spearman’s Rank correlation 
test. 
All statistical tests were considered sig-
nificant if p-value < 0.05. All data were ex-
pressed as mean +/- standard deviation 
(SD), median (95 % CI) and inter-quartile 
range (IQR). 
 
RESULTS 
During the recruitment period, 217 pa-
tients were admitted to UKM Medical Cen-
tre with an acute stroke. Fifty consecutive 
patients fulfilling all the inclusion and ex-
clusion criteria were enrolled into the study. 
The median age was 65.5 years (IQR 18) 
and 27 (54 %) patients were female. Twen-
ty-six (52.0 %) patients were Chinese, 21 
(41.0 %) were Malay and 3 (6.0 %) were 
Indian. There were 11 smokers; of these 10 
were male and one female. Baseline haema-
tological and biochemical parameters are 
shown in Table 1. 
Using the Bamford Oxford stroke clas-
sification, 20 (40 %) patients were admitted 
with Partial Anterior Circulation Syndrome 
(PACS), 18 (36 %) presented with Lacunar 
Syndrome, 7 (14 %) patients with Total An-
terior Circulation Syndrome (TACS) and 
the remaining 5 (10 %) patients presented 
with Posterior Circulation Syndrome (Bam-
ford et al., 1991). 
Seven out of 50 patients (14 %) were 
found to have biochemical aspirin re-
sistance. The median AUC was 258.0 
AUC*min (IQR 143.5). 
Using the Spearman’s Rank Correlation 
test, only HDL level had a statistically sig-
nificant negative correlation with AUC 
(r = -0.394; p = 0.005) (Figure 1). There 
were no significant correlations between 
age, haemoglobin, platelet, HbA1c, total 
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cholesterol, triglycerides, LDL, ALT, ALP, 
urea and creatinine with AUC (Table 2). 
The study population was then divided 
into aspirin resistant and non-aspirin re-
sistant groups based on the AUC 
(AUC*min  440, non-aspirin resistant; 
AUC*min > 440, aspirin resistant). 
Analysis using 2-test showed that there 
was no significant difference in ethnicity 
between the aspirin resistant group and the 
non-aspirin resistant group (p = 0.516). 
Although the results showed that 18.2 % of 
smokers were aspirin resistant and only 
12.8 % of non-smokers were resistant to 
aspirin, this was not statistically significant 
(p = 0.651). It was shown that 22.2 % of 
females were aspirin resistant as compared 
to only 4.3 % in males, but this was not sta-
tistically significant (p = 0.16). 
 
 
Table 1: Baseline characteristics of the study 
population 
Demographics (n=50) 
Age 65.5 (18.0)
Sex  
Male  
Female  
23 (46 %)
27 (54 %)
Race  
Malay  
Chinese 
Indians  
21 (42 %)
26 (52 %)
3 (6 %)
Smoking 
Yes  
No  
11 (22 %)
39 (78 %)
Metabolic parameters  
Haemoglobin (g/dL) 13.5 (2.8) 
Platelet ( x109 g/dL) 271.0 (115.5)
Haemoglobin A1c (%) 7.1 (2.7)
Total Cholesterol (mmol/L) 5.0 (2.1)
Triglycerides (mmol/L) 1.4 (0.7)
HDL (mmol/L) 1.1 (0.4)
LDL (mmol/L) 3.0 (1.9)
ALT (mmol/L) 17.5 (9.5)
ALP (mmol/L) 73 (34)
Urea (mmol/L) 5.5 (3.1)
Creatinine (umol/L) 70.5 (38.5)
Data is expressed as median (IQR). 
HDL: high density lipoprotein, LDL: low density lipoprotein,  
ALT: alanine transaminase, ALP: alkaline phosphatase 
Comparison between the two groups 
showed no significant differences for age, 
haemoglobin, platelet, HbA1c, total choles-
terol, triglycerides, HDL, LDL, ALT, ALP, 
urea and creatinine (Table 3). 
 
 
Figure 1: Correlation of HDL with AUC  
 
 
Table 2: Correlation of AUC with age, biochem-
ical, lipid and haematological profiles 
Variable 
Correlation 
coefficient 
(n=50) 
p- 
value 
Age (years) 0.098 0.498 
Haemoglobin (g/dL) 0.120 0.407 
Platelet (x109 g/dL) 0.041 0.775 
Haemoglobin A1c (%) 0.007 0.964 
Total Cholesterol 
(mmol/L) -0.074 0.611 
Triglycerides (mmol/L) 0.079 0.588 
HDL (mmol/L) -0.394 0.005*
LDL (mmol/L) 0.32 0.826 
ALT (mmol/L) 0.274 0.054 
ALP (mmol/L) 0.254 0.075 
Urea (mmol/L) 0.057 0.694 
Creatinine (umol/L) -0.139 0.337 
HDL: high density lipoprotein, LDL: low density lipoprotein, 
ALT: alanine transaminase, ALP: alkaline phosphatase; 
all data analysed using Spearman’s Rank Correlation test 
AUC; Area Under the Curve 
*Data is considered significant when p < 0.05 
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To further investigate the relationship 
between hyperglycaemia and aspirin re-
spone, patients were grouped using the 
HbA1c level as a surrogate marker. HbA1c 
 6.5 % were grouped as good glycaemic 
control whereas HbA1c > 6.5 % were labe-
led as poor control. 2 test did not show any 
significant statistical difference (p = 1.00). 
Aspirin resistance occurred in 14.3 % of pa-
tients with poor glycaemic control and 
13.8 % of patients with good glycaemic 
control. 
Patients receiving calcium-channel blo-
ckers, proton-pump inhibitors and HMG-
CoA reductase inhibitors (statins) during 
the 5 days of the study period were selected 
and the aspirin response was compared. 
Of those who were deemed to be aspirin 
resistant, 6 (85.7 %) patients were on statins 
whereas only one (14.3 %) patient was not. 
Analysis using 2-test showed that there 
was no statistically significant difference in 
the number of patients taking statins be-
tween the aspirin resistant group and non-
aspirin resistant group (p = 1.00). 
In the aspirin resistant group, 3 (42.9 %) 
patients were on a proton-pump inhibitor 
and 4 (57.1 %) of the patients were not. 
Analysis using 2-test showed that there 
was no statistically significant difference in 
the number of patients taking a proton-
pump inhibitor between the aspirin resistant 
group and non-aspirin resistant group 
(p = 0.345). 
 In the aspirin resistant group, 3 
(42.9 %) patients were on a calcium-
channel blocker and 4 (57.1 %) of the pa-
tients were not. Analysis using 2-test 
showed that there was no statistically sig-
nificant difference in the number of patients 
taking a calcium-channel blocker between 
the aspirin resistant group and non-aspirin 
resistant group (p = 1.00). 
 
 
 
Table 3: Comparison between aspirin resistant group and non-aspirin resistant group in terms of AUC, 
demographic and baseline parameters 
Variable Aspirin  Resistant (n=7) 
Non-Aspirin  
Resistant (n=43) p-value 
AUC (AUC*min) 615.0 (445.0) 227.0(107.0) < 0.001 
Age 72 (18) 65 (18) 0.493 
Haemoglobin (g/dL) 14.3 (4.5) 13.3 (2.4) 0.989 
Platelet (x109 g/dL) 301 (113) 260 (109) 0.275 
Haemoglobin A1c (%) 6.0 (3.9) 6.1 (2.5) 0.706 
Total Cholesterol (mmol/L) 5.12 (1.70) 4.96 (2.12) 0.605 
Triglycerides (mmol/L) 1.28 (0.82) 1.44 (0.72) 0.511 
HDL (mmol/L) 0.89 (0.44) 1.09 (0.36) 0.117 
LDL (mmol/L) 3.56 (1.21) 2.88 (1.88) 0.511 
ALT (mmol/L) 14.0 (25.0) 18.0 (9.3) 0.654 
ALP (mmol/L) 94.0 (33.0) 72.0 (33.3) 0.281 
Urea (mmol/L) 6.5 (4.2) 5.5 (2.8) 0.529 
Creatinine (umol/L) 68.0 (52.0) 72.0 (35.5) 0.655 
Data is expressed as median (IQR).  
All data analysed using Mann Whitney U test.  
Data is significant when p value is < 0.05. 
HDL: high density lipoprotein, LDL: low density lipoprotein, ALT: alanine transaminase, ALP: alkaline phosphatase 
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DISCUSSION 
This is a single-center cross-sectional 
observational study of 50 acute stroke pa-
tients who were aspirin-naïve. The evidence 
of biochemical aspirin resistance was de-
termined using in vitro impedance ag-
gregometry. 14 % of our patients were 
found to have aspirin resistance. It is diffi-
cult to make a meaningful head-to-head 
comparison between our studies and others 
due to differences in the methods of testing 
aspirin resistance. Previous studies on aspi-
rin resistance have reported a wide range of 
prevalence rate, ranging from 5 % to 45 % 
(Mason et al., 2005). Nonetheless, one stu-
dy investigating aspirin resistance in stroke 
patients in an Asian population found a 
prevalence rate of 12 %, which is compara-
ble to our finding (Seok et al., 2008). 
There is no cut-off value of HDL level 
that determines pathology or cerebrovascu-
lar disease. We therefore analysed the data 
to determine a correlation between HDL 
levels and AUC. We found that the HDL 
levels had a significant negative correlation 
with AUC (r = -0.394; p = 0.005). This 
suggests that a lower level of HDL may in-
crease the risk of aspirin resistance. In vitro, 
HDL inhibits thrombin, collagen, adenosine 
diphosphate and thrombin-induced binding 
of fibrinogen on platelets (non-COX-1 
platelet aggregation pathway), which may 
explain how HDL affects platelet function 
(Gum et al., 2003). Watala et al. (2004), us-
ing a different method to assess platelet 
function also found that a lower concentra-
tion of HDL levels amongst diabetic pa-
tients was associated with reduced aspirin-
induced platelet inhibition. In another 
study, Naqvi et al. (1999) demonstrated that 
a low HDL level is an independent predic-
tor of acute platelet-dependant thrombus 
formation. 
The majority of previous studies on as-
pirin resistance was conducted in countries 
that have a fairly homogenous population 
(Krasopoulos et al., 2008; Snoep et al., 
2007). The population of Malaysia is ethni-
cally heterogeneous. We had hoped to 
demonstrate a link between ethnicity and 
aspirin resistance. Although our study 
showed that there is no statistically signifi-
cant difference in prevalence of aspirin re-
sistance between the three different ethnic 
groups, our sample is too small for this to 
be a meaningful result. 
There have been several reports that 
have demonstrated possible risk factors for 
aspirin resistance. Some studies have 
shown that women and older patients are 
more likely to be aspirin resistant (Gum et 
al., 2001). Obesity, diabetes and anaemia 
have been described by certain authors to 
be factors for reduced aspirin-induced 
platelet inhibition (Watala et al., 2004; 
Tamminen et al., 2003). We found no sig-
nificant differences in demographic and 
other biochemical parameters between the 
groups who were aspirin resistant and those 
who were not. Our results are not unique as 
there have been other previous studies that 
have also published equally conflicting 
findings (Friend et al., 2003; Ozben et al., 
2011). It is not unusual for findings in dif-
ferent studies relating to risk factors for as-
pirin resistance to be contradictory and in-
consistent. In our study, this may be due to 
a small sample size. It also raises the ques-
tion whether the current methods to meas-
ure aspirin resistance requires further im-
provement.  
The relationship between biochemical 
aspirin resistance and clinical aspirin re-
sistance is being actively investigated. The 
present body of knowledge seems to sug-
gest that there is a direct relationship be-
tween the two but there is no worldwide 
consensus. Presently, clinical guidelines 
advocate the reduction of LDL levels in re-
ducing the rate of stroke recurrence. Our re-
sults open up the possibilities of addressing 
the role of modulating HDL as part of the 
strategy in the secondary prevention of 
stroke.  
Our findings could also be viewed from 
a socio-economic standpoint. If we can as-
sume that presence of biochemical aspirin 
resistance infers clinical aspirin resistance, 
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standard practice dictates that aspirin 
should be substituted with an alternative an-
ti-platelet agent. In the developing world, 
where clopidogrel is usually the alternative 
of choice, albeit an expensive one, increas-
ing HDL instead of prescribing clopidogrel 
has significant economic repercussions. Un-
fortunately, recent studies investigating this 
approach have so far been disappointing 
(Barter et al., 2007; Luscher et al., 2012). 
One of the major confounding factors in 
studies relating to aspirin resistance is the 
matter of compliance for aspirin in patients 
being studied. We addressed this issue by 
standardizing the method of aspirin admin-
istration and measurement of platelet func-
tion. We ensured that aspirin was taken un-
der direct supervision by a health personnel 
and the measurement of platelet function 
was performed by one personnel for all the 
patients to remove the effect of inter-
operator variability.  
The duration of aspirin therapy has been 
shown to influence the prevalence rate of 
aspirin resistance (Pulcinelli et al., 2004). 
We attempted to remove this variable by 
measuring for biochemical aspirin re-
sistance at a standard pre-determined total 
dosage of aspirin for all of our patients. It is 
hoped that this uniformity would make our 
results more scientifically robust.  
This study investigated the prevalence 
of biochemical aspirin resistance, as op-
posed to clinical aspirin resistance, i.e. re-
current stroke despite secondary prevention 
therapy. How our results translate into clin-
ical outcome cannot be answered by our 
study, as it was not designed to investigate 
this aspect. We are planning a follow-up 
study to see how many of our patients de-
velop recurrent stroke.  
There are several weaknesses in our 
study. Due to the small sample size, the 
prevalence of aspirin resistance in our study 
can hardly be extrapolated to the general 
stroke population, but our finding is still 
food for thought. Secondly, we had to fall 
back on the manufacturer’s recommenda-
tion for the level of biochemical aspirin re-
sistance, as we do not have the financial re-
sources to establish the level in our own 
population.  
 
CONCLUSION 
The prevalence of in vitro aspirin re-
sistance using the Multiplate platelet ana-
lyser in this study was 14 %. Low HDL 
levels were found to be associated with 
higher AUC levels, indicating that HDL 
may be associated with the development of 
aspirin resistance. 
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